AstraZeneca Unveils $50 Billion U.S. Investment, Including Major Manufacturing Facility in Virginia

AstraZeneca announced it will invest $50 billion in the U.S. by 2030, focusing on manufacturing and R&D facilities134.

A centerpiece of this effort is a multi-billion dollar manufacturing facility for drug substances to be built at a yet-to-be-determined site in Virginia—this will be the company's highest-priced plant ever13.

An initial $4 billion investment will go directly into Virginia, with the deal said to have been negotiated in just over a month, described as the company’s fastest-ever major agreement1.

The Virginia facility will primarily focus on manufacturing medicines for chronic diseases3.

AstraZeneca will also expand its R&D capabilities in Maryland and Massachusetts as part of this broader U.S. strategy3.

The move comes amid potential U.S. tariffs on imported pharmaceutical products, potentially up to 200%, prompting manufacturers to localize more operations1.

AstraZeneca aims to achieve $80 billion in global sales by 2030, with 50% of revenue projected to come from the U.S.13.

The company’s revenue last year was $54 billion, with 42% coming from the U.S.1.

This commitment is in addition to a previously announced $3.5 billion U.S. capital investment1.

The investment is expected to create highly skilled jobs and expand advanced pharmaceutical manufacturing in America14.

Sources:

1. https://www.fiercepharma.com/manufacturing/astrazeneca-plans-50b-investment-us-including-massive-plant-virginia

3. https://www.pharmtech.com/view/astrazeneca-to-invest-50-billion-in-us-manufacturing-and-r-d

4. https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html